Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279637 | 0.77 | CYP3A4 (0.32) | TDP1CYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL11505648 | 0.76 | TDP1 (0.39) | TDP1CYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL378987 | 0.76 | TDP1 (0.39) | TDP1CYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL29354465 | 0.75 | TDP1 (0.43) | TDP1CYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL4918590 | 0.74 | TDP1 (0.38) | TDP1CYP3A4ALDH1A1ESR1ESR2 | |
| SCHEMBL11390900 | 0.73 | TDP1 (0.41) | TDP1CYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL14311100 | 0.73 | TDP1 (0.36) | TDP1CYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL18840106 | 0.70 | CYP3A4 (0.30) | TDP1CYP3A4 | |
| SCHEMBL11525165 | 0.69 | TDP1 (0.41) | TDP1CYP3A4TSHRLMNAESR1 | |
| SCHEMBL2153910 | 0.69 | TDP1 (0.41) | TDP1CYP3A4TSHRLMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695220-A1 | PROCESSES FOR PRODUCING ALKYL ACRYLATE DIMERS | SPECIALTY OPERATIONS FRANCE (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-20250230119-A1 | PROCESSES FOR PRODUCING ALKYL ACRYLATE DIMERS | SPECIALTY OPERATIONS FRANCE (FR) | 2025-07-17 | — | — | US | disclosed |
| US-20240400593-A1 | BIS-AMINOPHOSPHINES AS CATALYSTS FOR THE DIMERIZATION OF ALKYL ACRYLATES | SPECIALTY OPERATIONS FRANCE (FR) | 2024-12-05 | — | — | US | disclosed |
| WO-2024213474-A1 | PROCESSES FOR PRODUCING ALKYL ACRYLATE DIMERS | SPECIALTY OPERATIONS FRANCE (FR) | 2024-10-17 | — | — | WO | disclosed |
| EP-4419500-A1 | PROCESSES FOR PRODUCING ALKYL ACRYLATE DIMERS | SPECIALTY OPERATIONS FRANCE (FR) | 2024-08-28 | — | — | EP | disclosed |
| EP-4419534-A1 | BIS-AMINOPHOSPHINES AS CATALYSTS FOR THE DIMERIZATION OF ALKYL ACRYLATES | SPECIALTY OPERATIONS FRANCE (FR) | 2024-08-28 | — | — | EP | disclosed |
| CN-118234704-A | Method for producing alkyl acrylate dimer | 法国特种经营公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118159546-A | Bis-aminophosphines as catalysts for dimerization of alkyl acrylates | 法国特种经营公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023066829-A1 | PROCESSES FOR PRODUCING ALKYL ACRYLATE DIMERS | RHODIA OPERATIONS (FR) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023066844-A1 | BIS-AMINOPHOSPHINES AS CATALYSTS FOR THE DIMERIZATION OF ALKYL ACRYLATES | RHODIA OPERATIONS (FR) | 2023-04-27 | — | — | WO | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-7358209-B2 | Polymerisation catalysts | INEOS EUROPE LIMITED (GB) | 2008-04-15 | — | — | US | disclosed |
| US-7358209-B2 | Polymerisation catalysts | INEOS EUROPE LIMITED (GB) | 2008-04-15 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
| WO-2006030192-A1 | POLYOLEFINS | INEOS EUROPE LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400593-A1 | BIS-AMINOPHOSPHINES AS CATALYSTS FOR THE DIMERIZATION OF ALKYL ACRYLATES | AASDHPPT, AGPS, ACR | TDP1 1152/4885CYP3A4 2515/4885TSHR 3889/4885 |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | TDP1 884/4885CYP3A4 4440/4885TSHR 2428/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | TDP1 884/4885CYP3A4 4440/4885TSHR 2428/4885 |
| US-20250230119-A1 | PROCESSES FOR PRODUCING ALKYL ACRYLATE DIMERS | HDHD5, ABHD5, HACL2 | TDP1 1213/4885CYP3A4 697/4885TSHR 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.